GENEVA — Swiss pharmaceuticals powerhouse Roche on Tuesday announced it plans to invest $50 billion in the United States over the next five years, creating 12,000 jobs.

The Basel-based company, whose array of products includes cancer medicines and multiple sclerosis treatment Ocrevus, said the investment would go toward high-tech research and development sites and new manufacturing facilities in several places, including California, Indiana, Massachusetts and Pennsylvania.

Some of the $50 billion in investments were already underway or planned for the next several years, Roche spokesperson Rebekka Schnell said in an email, adding that the company was not specifying how much was announced for the first time Tuesday.

The announcement comes as President Donald Trump has urged foreign businesses to invest more in the United States and as he announced sweeping tariffs this month on imports as part of an effort meant to reduce a large U.S. trade deficit with other nations when it comes to sales of goods.

Before the Trump administration backed off of its most stringent tariff plans, products imported from Switzerland had been set to face tariffs of 31% — more than the 20% tariffs on goods from the European Union. Switzerland is not a member of the 27-country bloc but is virtually surrounded by other EU countries.

Roche, in its statement, said that once the new, expanded manufacturing comes on line, the company “will export more medicines from the U.S. than it imports” — though it made no mention of tariffs. It also said its current U.S. operations include 25,000 workers, 15 R&D centers and 13 plants.